menu search

MBRX / Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event

Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17 th at 9:00 AM ET HOUSTON, Jan. 5, 2023 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (moleculin.com). Read More
Posted: Jan 5 2023, 08:45
Author Name: PRNewsWire
Views: 103064

MBRX News  

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

By Zacks Investment Research
September 22, 2023

Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up

Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarco more_horizontal

Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?

By InvestorPlace
September 15, 2023

Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?

Moleculin Biotech (NASDAQ: MBRX ) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors. Accord more_horizontal

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

By PRNewsWire
September 5, 2023

Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan more_horizontal

Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 11, 2023

Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klem more_horizontal

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

By PRNewsWire
August 3, 2023

Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast

HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company more_horizontal

Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

By PRNewsWire
June 13, 2023

Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Live webcast fireside chat on Wednesday, June 21 st at 1:30 PM ET HOUSTON , June 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Mo more_horizontal

Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 11, 2023

Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript

Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relation more_horizontal

MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates

By InvestorPlace
May 11, 2023

MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates

Moleculin Biotech (NASDAQ: MBRX ) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents. more_horizontal


Search within

Pages Search Results: